| Date | Title | Description |
| 29.10.2024 | AbbVie’s Bold Move: Acquiring Aliada Therapeutics for CNS Breakthroughs | In a strategic maneuver that echoes the age-old adage, "the early bird catches the worm," AbbVie has set its sights on the burgeoning field of central nervous system (CNS) therapeutics. The Chicago-based pharmaceutical giant annou... |
| 29.10.2024 | Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics | SAN FRANCISCO and SUZHOU, China, Oct. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 28.10.2024 | Pete du Pont Freedom Foundation Celebrates Innovation and Leadership at 2024 Freedom Award Ceremony | Innovation and Leadership Shine as Incyte and Reinventing Delaware Finalists Take Center Stage in Wilmington
Progress has made the world a better place. Progress is based on innovation, and innovation is based on freedom”
— Hervé HoppenotWI... |
| 19.10.2024 | The Dawn of a New Era in Drug Discovery: Sanyou Bio's Super-Trillion Molecule Library | In the bustling heart of Shanghai, a revolution is brewing in the world of pharmaceuticals. Sanyou Bio, under the visionary leadership of Lang Guojun, has unveiled a groundbreaking innovation: the super-trillion molecule library. This monum... |
| 17.10.2024 | Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint | SAN FRANCISCO and SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 08.10.2024 | Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer | SAN FRANCISCO and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 01.10.2024 | Innovent's Picankibart: A New Dawn for Psoriasis Treatment in China | In the ever-evolving landscape of biopharmaceuticals, Innovent Biologics has emerged as a beacon of hope for millions suffering from moderate to severe plaque psoriasis. The company recently announced that its New Drug Application (NDA) for... |
| 26.09.2024 | Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis | SAN FRANCISCO and SUZHOU, China, Sept. 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 19.09.2024 | Innovent Biologics: Pioneering New Frontiers in Cancer Treatment | In the world of oncology, the quest for effective treatments is relentless. Innovent Biologics, a biopharmaceutical company based in China, is at the forefront of this battle. Recently, they presented groundbreaking clinical data at the 202... |
| 18.09.2024 | Innovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 202... | SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 18.09.2024 | Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress | SAN FRANCISCO and SUZHOU, China, Sept. 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 12.09.2024 | Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024 | SAN FRANCISCO and SUZHOU, China, Sept. 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatme... |
| 11.09.2024 | Innovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLC | SAN FRANCISCO and SUZHOU, China, Sept. 11, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 10.09.2024 | Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation | SAN FRANCISCO and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 07.09.2024 | CytoTronics Secures $13.5 Million to Revolutionize Cell Biology | In the bustling world of biotechnology, CytoTronics has emerged as a beacon of innovation. The Boston-based company recently announced a significant milestone: a $13.5 million Series Seed 2 funding round. This infusion of capital is not jus... |
| 07.09.2024 | CytoTronics: Cell Biology Discovery Tech Company Raises $13.5 Million (Seed Extension) | CytoTronics, a pioneer of semiconductor-based platforms for discovery in cell biology, announced a $13.5 million seed extension financing and the appointment of Sameer Rohatgi of LYFE Capital to their Board of Directors.
New investor LYFE C... |
| 04.09.2024 | Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries | Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in Africa
INDIANAPOLIS and CAIRO, Sept. 4, 2... |
| 02.09.2024 | Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024 | SAN FRANCISCO and SUZHOU, China, Sept. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 29.08.2024 | Innovent and Lilly: Pioneering Paths in Biopharmaceuticals | In the ever-evolving landscape of biopharmaceuticals, two companies stand out: Innovent Biologics and Eli Lilly. Both are making waves, each with a unique approach to tackling pressing health issues. Innovent, based in Suzhou, China, is car... |
| 29.08.2024 | Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024 | SAN FRANCISCO and SUZHOU, China, Aug. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 28.08.2024 | Innovent Announces 2024 Interim Results and Business Updates | Strong commercial performance and significant pipeline milestones
support sustained growth and innovation
SAN FRANSISCO and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopha... |
| 22.08.2024 | China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China | SAN FRANCISCO and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 03.08.2024 | Innovent's Dual Approach to Diabetes and Hypertension: A New Era in Treatment | In the bustling world of biopharmaceuticals, Innovent Biologics is making waves. With two significant announcements in August 2024, the company is positioning itself as a key player in the treatment of chronic diseases like type 2 diabetes ... |
| 02.08.2024 | Innovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA) | SAN FRANSCISO and SUZHOU, China, Aug. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 01.08.2024 | Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update | – Axatilimab BLA in refractory chronic GVHD is under Priority Review; PDUFA action date of August 28, 2024 –
– Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 –
– Pivotal AUGME... |
| 30.07.2024 | MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte | Confirming cash runway guidance into 2026
ROCKVILLE, MD, July 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibo... |
| 30.07.2024 | MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte | ROCKVILLE, MD, July 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of... |
| 26.07.2024 | Advancing Dermatological Research: The American Skin Association's 2024 Grants**
** | ** The American Skin Association (ASA) has taken a bold step forward in the fight against skin diseases. On July 22, 2024, the ASA announced its 2024 research grants, a lifeline for scientists dedicated to understanding and treating skin co... |
| 26.07.2024 | BioVaxys and Innovent: Pioneering New Frontiers in Immunotherapy and Diabetes Treatment**
** | ** In the ever-evolving landscape of biopharmaceuticals, two companies are making waves: BioVaxys Technology Corp. and Innovent Biologics. Each is tackling significant health challenges with innovative approaches. BioVaxys is focused on imm... |
| 26.07.2024 | BioVaxys and American Skin Association: Pioneering Paths in Medical Research**
** | ** In the ever-evolving landscape of medical research, two organizations stand out: BioVaxys Technology Corp. and the American Skin Association (ASA). Each is carving a niche in their respective fields, focusing on innovative solutions for ... |
| 26.07.2024 | Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development | SAN FRANCISCO and SUZHOU, China, July 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 22.07.2024 | Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA | SAN FRANCISCO and SUZHOU, China, July 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 22.07.2024 | AMERICAN SKIN ASSOCIATION ANNOUNCES 2024 RESEARCH GRANTS FOR SKIN CANCER AND DISEASES | NEW YORK, July 22, 2024 /PRNewswire/ -- American Skin Association has announced the names of the three Investigative Scientist Awards. Andrew Ji, MD of Icahn School of Medicine at Mount Sinai was awarded the ASA Sanofi Investigative Scienti... |
| 18.07.2024 | Frost & Sullivan Institute Celebrates Leaders in Sustainability with 2024 Enlightened Growth Leadership Awards | SANTA CLARA, Calif., July 18, 2024 /PRNewswire/ -- The Frost & Sullivan Institute is excited to announce the winners of the 2024 Enlightened Growth Leadership Best Practices Recognition from the Americas (LATAM and North Americas). This... |
| 05.07.2024 | Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy | SAN FRANCISCO and SUZHOU, China, July 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 02.07.2024 | Innovent Announces Oral Presentation at the ESMO Gastrointestinal Cancers Congress 2024 on Latest Clinical Data of Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junctio... | SAN FRANCISCO and SUZHOU, China, July 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 28.06.2024 | Innovent Provides Interpretation and Updates on Clinical Data from Mazdutide GLORY-1 Study and General Biomedicine Pipeline | SAN FRANCISCO and SUZHOU, China, June 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 25.06.2024 | Innovent Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions | SAN FRANCISCO and SUZHOU, China, June 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 19.06.2024 | Innovent Reports Oncology Pipeline Updates at Investor Meeting | SAN FRANCISCO and SUZHOU, China, June 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 14.06.2024 | Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the ... | SAN FRANCISCO and SUZHOU, China, June 14, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 03.06.2024 | Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatme... | SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 03.06.2024 | Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer a... | SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 02.06.2024 | Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 02.06.2024 | Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 02.06.2024 | Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting | SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| 02.06.2024 | Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting | SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 21.05.2024 | Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease | SAN FRANCISCO and SUZHOU, China, May 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 20.05.2024 | Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC) | SAN FRANCISCO and SUZHOU, China, May 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for t... |
| 09.05.2024 | Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints | SAN FRANCISCO and SUZHOU, China, May 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment ... |
| 08.05.2024 | Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update | – NDA filing for revumenib in R/R KMT2Ar acute leukemia granted Priority Review under RTOR; PDUFA action date set for September 26, 2024 –
– BLA filing for axatilimab in chronic GVHD granted Priority Review; PDUFA action date set for August... |
| 07.05.2024 | Innovent Receives NMPA Breakthrough Therapy Designation for IBI343（Anti-Claudin18.2 ADC）as Monotherapy for Advanced Gastric Cancer | SAN FRANCISCO and SUZHOU, China, May 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for th... |
| 30.04.2024 | Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO) | SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 16.04.2024 | Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO) | SAN FRANCISCO and SUZHOU, China, April 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 08.04.2024 | Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 20.03.2024 | Innovent Announces 2023 Annual Results and Business Updates | A transformative year of strong performance and material innovation progress
ROCKVILLE, M.D. and SUZHOU, China, March 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that d... |
| 19.03.2024 | Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD) | ROCKVILLIE, Md. and SUZHOU, China, March 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines f... |
| 12.03.2024 | Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, March 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... |
| 05.03.2024 | Incyte Launches ‘The Unseen Journey’ to Elevate Impact of MPNs on Patients’ Lives via Generative AI | The Unseen Journey brings to life the often-misunderstood impact of common myeloproliferative neoplasm (MPN) symptoms through AI-generated images developed from the words and experiences of real patients
Incyte announced the launch of The U... |
| 04.03.2024 | Growth Trajectory Of Merkel Cell Carcinoma Treatment Market: Market Size To Reach $4.2 Billion By 2028 As Per The Business Research Company's Merkel Cell Carcinoma Treatment Global Market Report 2024 | Exclusive Offer By The Business Research Company - Get 33% Discount On Opportunities And Strategies Reports
LONDON, March 04, 2024 (GLOBE NEWSWIRE) -- As per The Business Research Company’s Merkel Cell Carcinoma Treatment Global Market Repo... |
| 04.10.2022 | Incyte to Acquire Villaris Therapeutics | Incyte (NASDAQ:INCY), a Wilmington, DE-based biopharmaceutical company, acquired Villaris Therapeutics, a Cary, NC-based asset-centric biopharmaceutical company.
Under the terms of the agreement, which is subject to clearance by the U.S. an... |
| 22.03.2022 | MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL | MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Minjuvi is a new therapeutic opti... |
| 28.01.2022 | Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis | INDIANAPOLIS, Jan. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) today announced updates on the Phase 3 development program for OLUMIANT® (baricitinib) in adults with active systemic lupus erythematosus... |
| 30.09.2021 | Incyte : OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata | INDIANAPOLIS, Sept. 30, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and BRAVE-AA2), which found once-daily OLUMIANT® (baricitin... |
| 03.08.2021 | Incyte : Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation | INDIANAPOLIS, Aug. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with COVID... |
| 29.07.2021 | Eli Lilly and : FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen | INDIANAPOLIS, July 29, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today the U.S. Food and Drug Administration (FDA) has broadened the Emergency Use Authorization (EUA) for baricitinib to allow ... |
| 28.07.2021 | Incyte : Announces Progress on Global Responsibility Initiatives and Sets Corporate Goals for the Next Four Years | ∙
∙
∙
∙
2
Attachments
Original document
Permalink
Disclaimer
Incyte Corporation published this content on 28 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 Jul... |
| 02.07.2021 | PACT held its annual Enterprise Awards IRL this week. Here’s who was honored | For the first time in about a year and a half, the Philadelphia Alliance for Capital and Technologies (PACT) gathered tech and healthcare innovators from across the region for an in-person event to celebrate the org’s annual Enterprise Awar... |
| 02.06.2021 | INCYTE CORPORATION
Incyte : OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses | INDIANAPOLIS, June 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present data from post-hoc analyses that suggested OLUMIANT® (baricitinib) 4 mg tablet reduced pain and duration of morning joint st... |
| 28.05.2021 | BB Biotech : investment trust review highlights long t... | Launched in 1993, BB Biotech (BION) is one of the largest specialist funds investing in the fast-growing sector of
biotechnology. It is managed by Bellevue Asset Management, a healthcare investment manager headquartered in Switzerland, and ... |
| 08.04.2021 | Eli Lilly and : Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients | INDIANAPOLIS, April 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo... |
| 11.03.2021 | Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021 | WILMINGTON, Del.--(BUSINESS WIRE)--Mar 11, 2021--
Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during Week 1 of the upcoming American Association for Cancer Research (AACR... |
| 11.02.2021 | MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte | ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today an... |
| 12.11.2020 | British biopharmaceutical company Grow Group PLC announces GBP 6 million Series C fundraise for cannabis market expansion
USA - English
Deutschland - Deutsch
France - Français | |
| 15.09.2020 | US based biopharmaceutical company Attralus raises US$ 25M Series A funding | - |
| 11.03.2020 | Biopharmaceutical Company Amunix Closes $73 Million In Funding | Amunix Pharmaceuticals, a biopharmaceutical company focused on developing prodrugs, announced it raised $73 million in an oversubscribed round of funding
Amunix Pharmaceuticals — a biopharmaceutical company focused on developing prodrugs to... |
| 30.09.2019 | Agios drug improves progression-free survival in Phase III cholangiocarcinoma study | A drug used to treat a form of adult leukemia has shown efficacy in a form of bile duct cancer that has no approved treatments.
On Monday, Cambridge, Massachusetts-based Agios Pharmaceuticals announced the presentation of data from its 185-... |
| 18.08.2019 | FDA approves first drug for blood disorder myelofibrosis since 2011 | Prior to Inrebic’s approval, the only drug approved for myelofibrosis was Incyte’s Jakafi (ruxolitinib), which the FDA approved in 2011. Both drugs belong to a class known as JAK inhibitors. Jakafi is intermediate or high-risk myelofibrosis... |
| 08.02.2017 | As hep C revenues decline, investors ask: Who is Gilead? | Sales of its chronic hepatitis C virus (HCV) treatments decreased from over $19 billion in 2015 to almost $15 billion in 2016. Looking ahead to 2017, the company expects between $7.5-$9 billion in revenue from its franchise — significantly ... |
| 07.10.2016 | Updated Incyte combo data for epacadostat/Keytruda look promising | Incyte this morning teed up a fresh look at data from its early-stage study of its closely watched IDO1 drug epacadostat combined with Merck’s PD-1 checkpoint therapy Keytruda. And the update — a little more than week after ... |
| 28.09.2016 | Incyte’s IDO1 update on its Keytruda combo scores some positive reviews | Incyte’s latest cut on the data from a Phase I/II study of its combination therapy adding Merck’s checkpoint star Keytruda to its closely watched IDO1 enzyme inhibitor epacadostat for melanoma is continuing to impress ob... |
| 08.04.2016 | Incyte snags rights to blood disease drug | The Wilmington-based biopharmaceutical company Incyte Corporation announced this week that it has bought the rights to develop and commercialize a drug with the potential to treat people suffering from graft-versus-host disease, which happe... |
| 08.04.2016 | Incyte snags rights to blood disease drug | The Wilmington-based biopharmaceutical company Incyte Corporation announced this week that it has bought the rights to develop and commercialize a drug with the potential to treat people suffering from graft-versus-host disease, which happe... |
| 21.07.2015 | Kris Vaddi is ditching big pharma for the startup life | If you ask Kris Vaddi, he’ll tell you the best time at Incyte Corp. was when the pharmaceutical company employed 20-30 people.
“The startup environment is really exciting. There’s a certain amount of energy and excitement that you have that... |
| 04.05.2015 | These bioscience pros were honored at the Delaware Bio Awards Gala | Hundreds of professionals across multiple industries gathered at the DuPont Country Club in Wilmington last month to recognize and honor seven individuals and one company for their exemplary work in bioscience.
The event: the Delaware Bio A... |
| 16.03.2015 | Newark’s trending right now [Events Roundup] | Newark has two great events happening this week: Delaware BioScience Association’s career fair with 100 job openings and the Delaware Tech Meetup with a featured keynote from SevOne. If you’re in Wilmington, don’t miss the Technology Forum ... |
| 11.11.2014 | 13 innovative technologies being developed in Delaware | The Delaware technology community may still be new to building web and software businesses. Its medical and chemical heritage, however, means the state has a leg up in developing and commercializing life sciences research.
From the lasting ... |
| 09.11.2012 | 5 things for startups to consider as they walk tightrope towards regulatory approval | Make sure you describe your company’s device or drug accurately Years before Capper joined CardioNet as CEO, its tool for diagnosing and monitoring cardiac arrhythmias was classified as a health service, not a medical device. Reimbursement ... |
| 08.06.2012 | Lilly’s rheumatoid arthritis drug using JAK inhibitors gets positive 2b results | Among the findings were baricitinib at 4 milligrams and 8 milligrams QD improved the signs and symptoms of rheumatoid arthritis over a 12-week period. There was significant difference against the placebo seen as early as week two for ACR20.... |
| 20.04.2012 | EU recommendation triggers $40M milestone payment for bone marrow disease drug | Known as Jakafi in the U.S., the drug was approved by the U.S. Food and Drug Administration in November last year.
Up to 18,000 people in the U.S. have myelofibrosis, a condition in which bone marrow is replaced with scar or fibrous tissue ... |
| - | Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC) | WILMINGTON, Del.--(BUSINESS WIRE)--Feb 26, 2021--
Incyte (Nasdaq:INCY) today announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for a... |
| - | As hep C revenues decline, investors ask: Who is Gilead? | Despite overdelivering on fourth quarter 2016 earnings, shares of Gilead Sciences dropped six points in overnight trading on Tuesday, on the back of poor 2017 sales estimates.
The investor reaction was summed up in the headline of a Seeking... |
| - | FDA approves first drug for blood disorder myelofibrosis since 2011 | The Food and Drug Administration has approved the first new drug for a type of rare blood cancer in nearly a decade.
The FDA said Friday that it approved Celgene’s Inrebic (fedratinib) for intermediate-2 or high-risk primary or secondary my... |
| - | Agios drug improves progression-free survival in Phase III cholangiocarcinoma study | A drug used to treat a form of adult leukemia has shown efficacy in a form of bile duct cancer that has no approved treatments.
On Monday, Cambridge, Massachusetts-based Agios Pharmaceuticals announced the presentation of data from its 185-... |
| - | EU recommendation triggers $40M milestone payment for bone marrow disease drug | A European Union regulatory committee’s recommendation to approve a drug developed by Incyte (NASDAQ:INCY) to treat the bone marrow disease myelofibrosis has triggered a $40 million milestone payment from Novartis (NYSE:NVS).
The recommenda... |
| - | Lilly’s rheumatoid arthritis drug using JAK inhibitors gets positive 2b results | Eli Lilly‘s (NYSE:LLY) rheumatoid arthritis treatment developed by drug developer Incyte (NASDAQ:INCY) using oral janus-associated kinases, or JAK, inhibitors, has produced positive phase 2b results, according to a company statement.
The re... |
| - | Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ve... | WILMINGTON, Del.--(BUSINESS WIRE)--Mar 18, 2021--
Incyte (Nasdaq:INCY) today announced results from the Phase 3 DEVENT study evaluating the efficacy and safety of ruxolitinib (5mg and 15mg) plus standard of care (SoC) versus SoC in patients... |
| - | 5 things for startups to consider as they walk tightrope towards regulatory approval | There are benefits for startup medical device and drug development companies to court regulators like the U.S. Food and Drug Administration early to ensure strong communication on what’s expected and what a comany’s product(s) can deliver. ... |
